Zynquista (sotagliflozin), an investigational oral treatment as an adjunct therapy to insulin for adults with type 1 diabetes, which received a split decision from an FDA advisory panel in January of this year, now awaits the final decision on March 22, 2019.Zynquista, developed by Sanofi (SNY) in partnership with Lexicon Pharmaceuticals Inc. (LXRX) is an oral dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys absorb and eliminate sugar (glucose), resulting in improved glucose control and additional clinical benefits.The FDA panel voted eight to eight that the overall benefits of Zynquista outweighed the associated risks last month. With a split verdict from the FDA panel, it remains to be seen what decision the FDA will take. After all, the regulatory agency considers the recommendations of its advisory panel even though it is not mandatory to act on them.According to GlobalData Healthcare, Zynquista is expected to reach peak U.S. sales of $1.3 billion in 2024.LXRX closed Tuesday’s trading at $5.48, down 0.18%.